Literature DB >> 31229883

2-Aminoimidazole-based antagonists of the 5-HT6 receptor - A new concept in aminergic GPCR ligand design.

Adam S Hogendorf1, Agata Hogendorf2, Rafał Kurczab2, Justyna Kalinowska-Tłuścik3, Piotr Popik2, Agnieszka Nikiforuk2, Martyna Krawczyk2, Grzegorz Satała2, Tomasz Lenda2, Joanna Knutelska4, Ryszard Bugno2, Jakub Staroń2, Wojciech Pietruś5, Mikołaj Matłoka6, Krzysztof Dubiel6, Rafał Moszczyński-Pętkowski6, Jerzy Pieczykolan6, Maciej Wieczorek6, Bogusław Pilarski7, Paweł Zajdel4, Andrzej J Bojarski2.   

Abstract

A new strategy in the design of aminergic GPCR ligands is proposed - the use of aromatic, heterocyclic basic moieties in place of the evergreen piperazine or alicyclic and aliphatic amines. This hypothesis has been tested using a benchmark series of 5-HT6R antagonists obtained by coupling variously substituted 2-aminoimidazole moieties to the well established 1-benzenesulfonyl-1H-indoles, which served as the ligands cores. The crystallographic studies revealed that upon protonation, the 2-aminoimidazole fragment triggers a resonance driven conformational change leading to a form of higher affinity. This molecular switch may be responsible for the observed differences in 5-HT6R activity of the studied chemotypes with different amine-like fragments. Considering the multiple functionalization sites of the embedded guanidine fragment, diverse libraries were constructed, and the relationships between the structure and activity, metabolic stability, and solubility were established. Compounds from the N-(1H-imidazol-2-yl)acylamide chemotype (10a-z) exhibited high affinity for 5-HT6R and very high selectivity over 5-HT1A, 5-HT2A, 5-HT7 and D2 receptors (negligible binding), which was attributed to their very weak basicity. The lead compound in the series 4-methyl-5-[1-(naphthalene-1-sulfonyl)-1H-indol-3-yl]-1H-imidazol-2-amine (9i) was shown to reverse the cognitive impairment caused by the administration of scopolamine in rats indicating procognitive potential.
Copyright © 2019. Published by Elsevier Masson SAS.

Entities:  

Keywords:  2-Aminoimidazole; 5-HT(6) antagonist; Alzheimer's disease; GPCR; Non-basic; Serotonin

Mesh:

Substances:

Year:  2019        PMID: 31229883     DOI: 10.1016/j.ejmech.2019.06.001

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro.

Authors:  Annamaria Lubelska; Gniewomir Latacz; Magdalena Jastrzębska-Więsek; Magdalena Kotańska; Rafał Kurczab; Anna Partyka; Małgorzata Anna Marć; Daria Wilczyńska; Agata Doroz-Płonka; Dorota Łażewska; Anna Wesołowska; Katarzyna Kieć-Kononowicz; Jadwiga Handzlik
Journal:  Molecules       Date:  2019-12-06       Impact factor: 4.411

2.  2-Phenyl-1H-pyrrole-3-carboxamide as a New Scaffold for Developing 5-HT6 Receptor Inverse Agonists with Cognition-Enhancing Activity.

Authors:  Marcin Drop; Vittorio Canale; Séverine Chaumont-Dubel; Rafał Kurczab; Grzegorz Satała; Xavier Bantreil; Maria Walczak; Paulina Koczurkiewicz-Adamczyk; Gniewomir Latacz; Anna Gwizdak; Martyna Krawczyk; Joanna Gołębiowska; Katarzyna Grychowska; Andrzej J Bojarski; Agnieszka Nikiforuk; Gilles Subra; Jean Martinez; Maciej Pawłowski; Piotr Popik; Philippe Marin; Frédéric Lamaty; Paweł Zajdel
Journal:  ACS Chem Neurosci       Date:  2021-03-11       Impact factor: 4.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.